Disc Medicine, Inc. (IRON) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 30.36M USD | Liabilities, Current |
| Cash and equivalents | 98.68M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 619.07M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $30.36M | $98.68M | $619.07M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $31.14M | $88.91M | $641.25M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $36.64M | $91.14M | $700.01M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $26.74M | $140.66M | $475.26M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $20.61M | $127.34M | $522.64M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $18.74M | $122.67M | $571.99M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $23.32M | $192.43M | $297.45M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $25.47M | $192.64M | $294.73M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $20.31M | $280.66M | $220.28M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $14.85M | $342.62M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $21.44M | $360.38M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $14.42M | $370.54M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $9.68M | $377.60M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $9.98M | $236.42M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $22.58M | $194.61M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.46M | $101.74M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $6.44M | $108.66M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $12.67M | $119.06M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $14.83M | $136.63M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $12.66M | $150.07M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $11.51M | $167.48M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $13.78M | $184.99M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $597.57K | $1.21M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $552.40K | $1.44M | (m) | (m) | (m) | (m) |
| 2020-06-24 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |